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404Six-minute walk test closely correlates to “real-life”
outdoor walking capacity and quality of life in
patients with intermittent claudication
Joakim Nordanstig, MD, Monica Broeren, RN, Marlene Hensäter, RN, Angelica Perlander, MD,
Klas Österberg, MD, PhD, and Lennart Jivegård, MD, PhD, Gothenburg, Sweden
Objective: We used outdoor walking distance measured during 40 minutes as “real-life” outdoor walking capacity in 49
patients with intermittent claudication (IC). The outdoor walking distance was measured by a global positioning system
application for a smartphone. The relationships of self-reported maximum walking distance (SR-MWD), the MWD on a
graded treadmill test, and the 6-minute maximumwalk distance (6MWD) vs outdoors walking capacity were investigated.
Also studied were the associations of SR-MWD, MWD, and 6MWD with health-related quality of life assessed with the
disease-speciﬁc instrument the Vascular Quality of Life Questionnaire (VascuQoL).
Methods: In this prospective observational cohort study, 49 IC patients underwent an outdoor walking capacity test for
40 minutes, and MWD and 6MWD were measured. SR-MWD was recorded, and all subjects completed the VascuQoL
questionnaire. Associations between the different walk estimates and outdoor walking capacity and health-related quality
of life were investigated by correlation analysis (Spearman r).
Results: Outdoor walking distance during 40 minutes was a median 2495 m (range, 1110-3300 m). SR-MWD correlated
moderately and MWD correlated strongly to outdoor walking capacity (r [ 0.56 and r [ 0.65; P < .001, respectively).
The 6MWD test showed the largest correlation to the outdoor walking capacity (r[ 0.78; P < .001). The 6MWDwas the
only test that showed correlations with the VascuQoL sum score (r[ 0.53; P < .01) and all of the domain scores, whereas
SR-MWD and MWD showed weak correlations to the VascuQoL.
Conclusions: The distance walked during the 6-minute walk test is closely correlated to outdoor walking capacity and
health-related quality of life in IC patients. Our data support the use of 6MWD for routine clinical evaluation of walking
capacity in IC patients. (J Vasc Surg 2014;60:404-9.)Intermittent claudication (IC) may cause considerable
functional walking impairment, reducing health-related
quality of life (HRQOL).1,2 Although relying on very low
or low3 quality of evidence,4 invasive vascular interventions
are often considered to improve walking capacity in IC pa-
tients.5 In clinical practice, self-reported maximum walking
distance (SR-MWD) constitutes an important determinant
for offering invasive treatment. However, SR-MWD may
be an unreliable tool for the evaluation of walking capacity6
in IC patients, and hence, the estimation of walking impair-
ment in IC remains challenging.7,8 Several scoring systems
and walk tests have been introduced to more objectively
deﬁne walking capacity and limitations. These include tread-
mill tests,9 corridor walk tests,10 patient-reported walking
impairment questionnaires,11 and disease-speciﬁc HRQOLthe Department of Vascular Surgery and Institute of Medicine,
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the optimal clinical assessment tool for walking capacity
in IC.
A graded treadmill test is probably the most widely rec-
ommended walk test. The test is typically used as the pri-
mary outcome measure in IC interventional clinical trials.
However, treadmill tests represent tightly regulated proto-
cols constituting a relatively artiﬁcial measure of walking
capacity.10 Thus, changes in treadmill test results might
not correlate well with symptom relief after interventions
in patients with claudication.13 Moreover, the consistency
between treadmill test results and ambulatory function dur-
ing free-living physical activities has been questioned.7,10
Because IC patients usually are hampered only during out-
door walking, a longer outdoor walk is likely to reﬂect the
individual’s walking limitations. Assessment of walking dis-
tance during outdoor activities is possible with the use of
global positioning system (GPS) devices.14 GPS results
have been shown to correlate more closely than treadmill
test results to validated self-reported symptom scores.15
Our primary aim with this study was to explore the
relationships of SR-MWD, MWD on a graded treadmill
test, and the MWD on a 6-minute walk test (6MWD),
respectively, to the “real-life” outdoor walking capacity.
We hypothesized that the 6MWD would closely correlate
(r> 0.5) with the outdoor walking capacity.We also studied
the relations between the different walk tests and HRQOL,
assessed with the disease-speciﬁc HRQOL instrument
Vascular Quality of Life Questionnaire (VascuQoL).
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Study population. Patients visiting the vascular surgi-
cal outpatient clinic due to established mild, moderate, or
severe IC (Rutherford stage 1-3), without any other
activity-limiting medical condition, and age of #85 years
were eligible for the study. A senior vascular surgeon
established the diagnosis of vascular claudication from the
medical history, a full clinical vascular examination, and the
measurement of the ankle-brachial index (ABI). An ABI of
#0.9 combined with typical IC symptoms was required for
participation. Exclusion criteria were inability to under-
stand Swedish language (due to the use of the Swedish
version of the VascuQoL), thromboembolic etiology, and
weight >120 kg (maximum possible load on the treadmill).
Every participant provided written informed consent.
The ﬁrst 21 patients were recruited from an on-going
IC interventional trial, and 28 patients were thereafter
recruited from consecutive IC referrals to the vascular sur-
gical outpatient clinic, resulting in a sample of 49 patients.
All patients received structured, nonsupervised training
advice. Every patient without contraindications also
received aspirin (75 mg once daily) and statin therapy.
Patients with hypertension or diabetes, or both, were
referred to their general practitioner for additional medical
management.
“Real-life” outdoor walking capacity. We deﬁned
outdoor walking capacity as total walking distance during
a 40-minute outdoor test walk, measured according to a
previously described technique.16 In summary, an iPhone 4
(Apple Corp, Cupertino, Calif) smartphone equipped with
Walkmeter 10.0.3 (Abvio Inc, San Francisco, Calif),17 a
GPS-based walking performance application, was used for
the assessment of outdoor walking. We studied the preci-
sion of the Walkmeter distance-recording software in a
pilot test on a track-and-ﬁeld arena during 22 consecutive
walks around the 400-m track.
The outdoor test walk was situated in a ﬂat park area
during stable and similar weather conditions (temperature
>10C, light winds, and no rain) on every occasion. After
10 minutes of rest after arrival, the smartphone was
attached to the patient’s right upper arm, and the patient
was instructed to walk at his or her normal walking pace,
to stop walking when demanded by claudication pain,
but to proceed walking after recovery. Adequate satellite
coverage was conﬁrmed before the walk was initiated.
The test was performed individually and was timed and
monitored by a research nurse or the corresponding
author. The outdoor walk test was performed within
3 weeks after the indoor walking assessments.
Walk tests evaluated against “real-life” outdoor
walking capacity
Self-reported walking distance. The SR-MWD was
obtained by the following question: “What is the maximum
distance (in meters) you can walk at your usual pace on a
ﬂat surface before leg pain forces you to stop?” A research
nurse recorded the answer to this question during the samevisit as the patient attended the vascular laboratory for in-
door walk tests (ie, 6-minute walk and treadmill test). The
answer was recorded before any objective walking assess-
ments had been performed. This estimate was included in
the study because it probably represents the most common
way to assess walking capacity in IC.
Graded treadmill test. A research nurse supervised the
treadmill test. Before proceeding with a treadmill test, all pa-
tients were questioned about possible cardiac symptoms,
and a blood pressure at rest was measured. Testing was
allowed if the patient did not report recently debuted or
increasing cardiac symptoms (eg, chest pain or dyspnea)
and the blood pressure was <190/90 mm Hg. We used
our standard graded treadmill protocol with an increasing
workload due to progressively increasing slope (0%-12%)
and speed. The ﬁrst 2 minutes were completed at 0 and
1.5 km/h. After 2 minutes, the slope was increased to
12% (6.9). After 3 minutes, speed was continuously
incremented with 0.1 km/h every tenth second until the pa-
tient stopped. The MWD in meters on the treadmill was
recorded. Thirty individuals performed the treadmill test
before the 6-minute walk, whereas 19 did the treadmill
test after the 6-minutes walk. Every patient was allowed to
rest for at least 10 minutes before proceeding with the next
test. The graded treadmill test was included in the study
because it is recommended for outcome assessment in IC in
different clinical guidelines.18
The 6-minute walk test. We conducted the 6-minute
walk test as described by Guyatt et al.19 A hospital corridor
was used, and a distance of 30.5 m was outlined with ﬂoor
markings at each end. Patients were instructed to walk
from end to end at their own pace, attempting to cover as
much distance as possible. A research nurse timed the walk
and recorded the total covered distance. Patients were
allowed to stop and rest as demanded by claudication pain
but were encouraged to continue walking after recovery.
At the end of the test, the total covered distance was
recorded, rounded off to the nearest meter (6MWD). This
test was included in the study because it has been suggested
to correlate more closely to everyday ambulatory function
than treadmill testing.10
The VascuQoL. The VascuQoL, validated in Swed-
ish,20 is recommended as a disease-speciﬁc questionnaire
for HRQOL outcome measurement in patients with pe-
ripheral arterial disease.21,22 It consists of 25 items, sub-
divided into the ﬁve domains of pain, symptoms, activity,
social, and emotional. Each question has a 7-point response
scale. An overall total score and ﬁve domain scores are
calculated, ranging from 1 (worst HRQOL) to 7 (best
HRQOL). The patient independently completed the
questionnaire while attending the vascular laboratory for
the indoor walking tests. VascuQol has been shown to
correlate closely to outdoor walking capacity in IC
patients.16
Statistical analysis. Statistical analysis was performed
using SPSS 20.0 software (IBM Corp, Armonk, NY).
Means and standard deviations (SDs) or medians and
ranges (all walk test results) were calculated for continuous
Table I. Demographics and risk factors in the studied
population
Variables Value (N ¼ 49)
Age, mean (SD), years 70 (6)
Sex, %
Male 49
Female 51
Smoking habit, %
Current smoker 29
Previous smoker 41
Nonsmoker 30
Hypertension, % 76
Diabetes, % 8
Coronary disease/heart failure, % 27
Cerebrovascular disease, % 10
Pulmonary disease, % 18
Rutherford classiﬁcation, %
Category 1 (mild IC) 43
Category 2 (moderate IC) 37
Category 3 (severe IC) 20
Lowest ABI, mean (SD) 0.6 (0.2)
ABI, Ankle-brachial index; IC, intermittent claudication; SD, standard
deviation.
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variables. The relationships among the different clinical walk
assessments (SR-MWD, treadmill MWD, and 6MWD) and
outdoor walking capacity and HRQOL, respectively, were
explored using nonparametric measures of statistical depen-
dence (Spearman r). With regard to the precision of the
smartphone GPS application, test-retest reliability was
assessed by analyzing the coefﬁcient of variation (CV) and the
proportion of observations within 610% from the known
distance. Signiﬁcance was assumed at P < .05.
Ethical considerations. Ethical approval was obtained
from the University of Gothenburg Regional Ethical Re-
view Boards (No. 501/2009).
RESULTS
Precision of the smartphone GPS application
measurements. During the 22 consecutive pilot tests on the
400-m track-and-ﬁeld arena, adequate recordings were
captured during 100% of the walks. Median captured walk
distanceduring the testwalkswas415m(range,390-450m),
and 21 (96%) of the recordings were at 400 m 610%. The
CV was 3.1% (95% conﬁdence interval [CI], 2.4%-4.5%).
Study population. Demographic data and risk factors
are given in Table I. Mean age was 70 years (SD, 6 years)
and 49% were males. According to the Rutherford classi-
ﬁcation, 21 patients (43%) were categorized as Rutherford
stage 1 (mild claudication), 18 (37%) as Rutherford stage 2
(moderate claudication), and 10 (20%) as Rutherford stage
3 (severe claudication). Mean ABI was 0.6 (SD, 0.2) in the
most symptomatic leg. Eight of the 49 patients had pre-
viously received a vascular intervention (endovascular aor-
toiliac intervention, n ¼ 3; endovascular femoropopliteal
intervention, n ¼ 4; endarterectomy of the common
femoral artery, n ¼ 1).
Outdoor walking capacity and walk test results.
Median outdoor walking distance during the 40 minutes
outdoor test walk was 2495 m (range, 1110-3300 m).
Regarding the walk tests, median SR-MWD was 200 m
(range, 25-1000 m), MWD on graded treadmill was 175 m
(range, 58-507 m), and the 6MWD was 399 m (range,
183-523 m). Logistic regression (including age, gender,
current smoking, diabetes, and cardiovascular disease)
showed, that age (P ¼ .02) was the only independent
predictor of an outdoor walking distance of <2500 m.
Relationship between the different walk tests and
outdoor walking capacity. The associations between out-
door walking capacity and the different clinical walk assess-
ments are given in the Fig. Correlations with outdoor
walking capacity were moderate for the SR-MWD (r ¼
0.56; 95% CI, 0.33-0.73; P <.001) but were strong for
MWD (r ¼ 0.65; 95% CI, 0.45-0.79; P < .001) and the
6MWD (r ¼ 0.78; P < .001). The 6MWD was the only
walk test with the lower limit for the 95% CI >0.5 (95%
CI, 0.64-0.87).
Relationship between the different walk tests and
the VascuQoL. The correlation patterns between the
different walk assessments and the VascuQoL are reported
in Table II. Among the different walk tests, 6MWD wasthe only test that showed correlations with the VascuQoL
sum score and all of the domain scores. The treadmill
performance (MWD) correlated to the VascuQoL sum
score and to the activity and pain domain scores. SR-MWD
showed a correlation to the VascuQoL sum score and to
only the activity domain score.
DISCUSSION
In this study, we used the recorded outdoor walking
distance during 40 minutes as “real-life” outdoor walking
capacity. The primary ﬁnding is that the 6MWD closely
reﬂects (r ¼ 0.78; 95% CI, 0.64-0.87) the “real-life” out-
door walking capacity, conﬁrming our primary hypothe-
sis. Moreover, the 6MWD correlated to all aspects of
the HRQOL assessed with the disease-speciﬁc instrument
VascuQoL. Because only a minority of IC individuals is
limited during normal indoor activities, the walking dis-
tance during a longer outdoor walk at a normal pace is,
in our opinion, likely to reﬂect true ambulatory function
and walking limitations as experienced by IC patients.
We used walking distance outdoors during 40 minutes
as a pragmatic way to assess “real-life” walking capacity,
because a patient with IC is likely to experience walking
limitations during a 40-minute walk. The smartphone
GPS-based application to record walking distance had a
precision (CV ¼ 3.1%) similar to that observed in previ-
ous reports (CV ¼ 2.8%) that used dedicated GPS
recorders.23
The 6MWD test is easy to perform and demands prac-
tically no extra equipment or resources. Because the patient
regulates the walk intensity during the 6MWD, it should
be possible and safe to perform the test also in older pa-
tients and in patients with comorbidities such as heart dis-
ease or chronic pulmonary disease. Validity of the 6MWD
Fig. Correlation scatterplots show comparisons between global positioning system (GPS)-assessed outdoor walking
capacity and the walking capacity estimates for (left) self-reported maximum walking distance (SR-MWD), the (right)
MWD on a graded treadmill test, (bottom) and the 6-minute walk distance (6MWD). The ﬁtted lines are based on the
assumption of linear correlations.
Table II. Correlation pattern (Spearman r) between the different walking tests and the Vascular Quality of Life
(VascuQoL) total and domain scores
Variable
VascuQoL scores
Activity Symptom Pain Emotional Social Total sum
SR-MWD 0.40a 0.3 0.32 0.24 0.23 0.37a
MWD 0.37a 0.23 0.40a 0.27 0.2 0.34a
6MWD 0.57b 0.38a 0.52b 0.39a 0.38a 0.53b
6MWD, 6-minute maximum walking distance; MWD, maximum walking distance during graded treadmill test; SR-MWD, self-reported maximum walking
distance.
aP < .05 level (two-tailed).
bP < .01 level (two-tailed).
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retest reliability of the test is generally good, and strong
evidence supports responsiveness to clinical change in similar
medical settings.25 The 6MWD therefore seems to be an
appropriate test to use for clinical evaluation and follow-up
of walking limitations in IC and also in clinical trials.The graded treadmill test, recommended as the
preferred evaluation tool of walking limitations in IC,18,26
also correlated to outdoor walking capacity and some as-
pects of HRQOL in our study, but the correlations vs out-
door walking capacity (r ¼ 0.65; 95% CI, 0.45-0.79) were
not as strong as for the 6MWD. Essentially, the graded
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logic capacity and, as such, a test of general condition as
well as of walking capacity. It may not be the most optimal
test for the evaluation of functional limitations in IC. In a
previous study by our group, we showed that invasive treat-
ment of IC subjects signiﬁcantly reduced claudication pain
as a reason to stop during treadmill testing, whereas not
signiﬁcantly improving maximum walking performance.27
Even when considering the advantages of graded treadmill
testing (well-established, high reproducibility; useful diag-
nostic tool; characterizes the walking distance until onset
of IC symptoms and also the maximum possible covered
distance),28 our data lend some additional support to ques-
tion the graded treadmill test as the sole walk test for eval-
uation of IC subjects.
With regard to the SR-MWD, we conﬁrmed the results
from earlier studies,6,29 again illustrating that this estimate
of walking capacity is unreliable and correlates rather
poorly to real-life outdoor walking capacity (Fig) and
HRQOL. These ﬁndings might be explained by differences
in individual perception of walking limitations. Younger pa-
tients experiencing more functional limitations (and hence
more frustration) compared with their peers might under-
estimate their walking capacity, whereas elderly patients
managing relatively well during daily life might overesti-
mate it.
Ideally, any clinically used walk test in IC patients
should accurately reﬂect free-living ambulatory function.
Real-time assessment of ambulatory function is possible
by the use of physical activity monitors (pedometers and
accelerometers) or a GPS-equipped device, as used in our
study. Measurement of outdoor MWD distance by GPS
has previously been shown to correlate strongly with
MWD during treadmill testing in IC patients.14 Moreover,
the outdoor MWD correlates more closely than treadmill
test results to self-reported validated symptom scores.15
In our study we showed that a readily available smartphone
GPS recording procedure had reasonable precision. We
assessed outdoor walking capacity by recording the total
covered distance, including stops, during a 40-minute test
walk. The increasing availability of GPS technology could
allow most IC patients to perform real-time assessments of
walking ability in daily life, and the technique might be
possible to use in, for example, optimized supervised
training and rehabilitation programs and in remote follow-
up programs for IC patients.30,31 The GPS technique may
allow clinicians to tailor home-based exercise programs to
individual IC patients in which the patients could accurately
self-monitor progress and effort invested in training.
However, one drawback with such monitoring is the
need for special equipment, and proper use also places
additional demands on the patient and health-care
personnel that may not be practical in clinical routine set-
tings.32 A simpler test like the 6-minute walk test may
thus have an important role to play in the routine clinical
evaluation of IC subjects, especially because our data sup-
port that the 6MWD closely mirrors both outdoor walking
capacity and HRQOL.Limitations in our study include the relatively small pa-
tient sample. However, our primary hypothesis was
conﬁrmed, and although the sample size was small, our pa-
tients were representative for IC patients in general. The
demographic data of our present patient sample compares
well with corresponding data from our latest randomized
controlled trial, in which we included w60% of all eligible
claudicant patients at our unit.27 Furthermore, age and
gender distribution in our sample matches well with corre-
sponding ﬁgures regarding invasively treated IC patients
from the Swedish national vascular surgery registry.5 It
would have been interesting to include also a constant
load treadmill protocol for additional comparison, and we
recognize this as another weakness with our study design.
Although the CVwas similar to that previously reported
for GPS trackers, the lack of exact precision with regard to
the GPS measurements might have inﬂuenced our results.
Finally, because the outdoor walk tests were not performed
on the same day as the other walking tests and HRQOL
registrations, we cannot exclude that the timely separation
may have somewhat distorted our data.
CONCLUSIONS
Our data support the use of the 6-minute walk test in
the clinical evaluation algorithm among IC patients,
because this test reﬂects “real-life” outdoor walking capac-
ity and HRQOL. The use of a commonly available smart-
phone GPS application has a reasonable precision for the
assessment of “real-life” outdoor walking distance in IC
patients.
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